David Oh


Medical oncologist
Immunotherapy researcher

Dr. David Oh is a medical oncologist who cares for patients who are receiving novel immunotherapies for cancers as part of clinical trials. These are treatments that harness the patient's own immune system to fight cancer. He specializes in prostate and bladder cancers.

Oh's research focuses on understanding and improving cancer immunotherapies. He leads clinical trials to evaluate new immunotherapies for solid tumors, and he studies samples from patients who have received immunotherapies with the goal of better understanding their benefits and side effects.

Oh earned his medical degree from Stanford University School of Medicine, where he also completed a doctorate in physiology. At UCSF, he completed a residency in internal medicine and a fellowship in hematology and oncology.

Oh is a member of the American Society of Clinical Oncology, American Association for Cancer Research and Society for Immunotherapy of Cancer. He has received Young Investigator Awards from the Prostate Cancer Foundation, Bladder Cancer Advocacy Network and Conquer Cancer Foundation of the American Society of Clinical Oncology.

  • Education

    Stanford University School of Medicine, MD, 2011

    Stanford University School of Medicine, PhD, Molecular and Cellular Physiology, 2011

  • Residencies

    UCSF, Internal Medicine, 2014

  • Fellowships

    UCSF, Hematology/Oncology, 2017

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Internal Medicine, American Board of Internal Medicine

  • Academic Title

    Assistant Professor

I am committed to offering the latest immunotherapies to all cancer patients, and helping each patient find the kind of clinical trial that is the best fit for them.

Clinics I work with

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

Decorative Caduceus

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prosta...

Incidence and severity of treatment-emergent adverse events


Decorative Caduceus

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Ce...

TIICs will be analyzed in pre- and post-pembrolizumab-based treatment tumor specimens. The proportion of participants with a >=2-fold increase (from pre- to post-treatment) in the number of TIICs will be calculated.


Decorative Caduceus

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in ...

Dose limiting toxicity (DLT) is defined as protocol-defined adverse events that occur within 28 days following infusion of Neo-TCR-P1 administered as a single agent without or with IL-2, or in combination with nivolumab.


Decorative Caduceus

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer


Decorative Caduceus

Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumor...

The proportion of participants who show clinical benefit, defined as complete response (CR), partial response (PR), or stable disease (SD) for ≥ 6 months as best response by RECIST v1.1